CLDI
Calidi Biotherapeutics, Inc.
Key Financials
Operating Income
$-20240000
↑ 7.1%
Net Income
$-19906000
↑ 10.1%
Revenue
$45000
N/A
Total Liabilities
$5.1M
↓ 58.3%
Total Assets
$8.9M
↓ 37.5%
Shareholders' Equity
$3.8M
↑ 145.0%
EPS (Diluted)
$-5.95
↓ 100.3%
Long-term Debt
$600000.00
0.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| PRE 14A | 4/17/2026 | View on SEC |
| 8-K | 4/2/2026 | View on SEC |
| SCHEDULE 13D | 3/31/2026 | View on SEC |
| 10-K | 3/27/2026 | View on SEC |
| 8-K | 3/27/2026 | View on SEC |
| 8-K | 3/11/2026 | View on SEC |
| SCHEDULE 13D | 3/9/2026 | View on SEC |
| 424B5 | 3/9/2026 | View on SEC |
| 424B5 | 3/6/2026 | View on SEC |
| S-3MEF | 3/5/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CLDI |
| Company Name | Calidi Biotherapeutics, Inc. |
| CIK | 1855485 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Emerging growth company |
| Exchange | NYSE |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 858-794-9600 |